{"id":"W4310753448","doi":"10.1016/j.annonc.2022.10.194","title":"157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Olaparib; Abiraterone; Placebo; Internal medicine; Oncology; Biomarker; Prostate cancer; Pathology; Cancer; Alternative medicine; Nuclear magnetic resonance","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002411626,0.0008900156,0.001632877,0.0006398668,0.000278572,0.001934805,0.0005937362,0.0006022287,0.004031317],"category_scores_gemma":[0.003139054,0.0003413128,0.001931223,0.001402791,0.0003126468,0.0008794742,0.0005234126,0.001261988,0.000795479],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000741737,"about_ca_system_score_gemma":0.001520946,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001270359,"about_ca_topic_score_gemma":0.004166375,"domain_scores_codex":[0.9990714,0.0003570211,0.00006745255,0.0001449769,0.0002299077,0.0001293516],"domain_scores_gemma":[0.9982581,0.0004900228,0.0006328395,0.0001321055,0.0002537145,0.0002332229],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5124859,0.002269155,0.1159769,0.003367689,0.01990859,0.0004719019,0.0001578286,0.003059634,0.02006444,0.0006640258,0.02807045,0.2935036],"study_design_scores_gemma":[0.180958,0.05029693,0.6275083,0.0007697862,0.04136888,0.001996937,0.000218427,0.002254467,0.01100734,0.002624955,0.08073454,0.0002614366],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8965814,0.0451773,0.001934575,0.003783947,0.001020419,0.000902615,0.0392406,0.0002712462,0.01108789],"genre_scores_gemma":[0.9264655,0.009476579,0.003711172,0.003235682,0.0007913524,0.0007877419,0.04943597,0.00009952593,0.005996398],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004031317,"threshold_uncertainty_score":0.01348615,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0927244702327429,"score_gpt":0.408633134894925,"score_spread":0.3159086646621821,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}